UBS Group
CCCC icon

UBS Group’s C4 Therapeutics CCCC Stock Holding History

UBS Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30,000
Closed -$226K – 10372
2022
Q2 		$226K Buy
+30,000
New +$264K ﹤0.01% 4815

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's CCCC Position: Q2 2026 in Review

UBS Group increased its C4 Therapeutics (CCCC) stake by 284% in Q2 2026, buying an estimated $2.1M and bringing the position to 828,970 shares worth $3.87M. The position accounts for ﹤0.01% of the portfolio, ranked #4429.

UBS Group first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $18.6M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • UBS Group held 828,970 shares of C4 Therapeutics worth $3.87M as of Q2 2026.
  • UBS Group bought 613,093 C4 Therapeutics shares in Q2 2026, an estimated $2.1M.
  • C4 Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4429 holding.
  • UBS Group first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • UBS Group's C4 Therapeutics position peaked at $18.6M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.